Regenxbio, a prolific developer of gene therapy technology, will hand Japan’s Nippon Shinyaku certain rights to two ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Security was tight for the first day of the J.P. Morgan Healthcare Conference, which featured two deals involving privately ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Regulatory complexity isn’t the only challenges clinical services organizations face in the APAC market. Cheong points to ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...